Literature DB >> 25339200

Escherichia coli antibiotic resistance in emergency departments. Do local resistance rates matter?

O Grignon1, E Montassier, S Corvec, D Lepelletier, J-B Hardouin, J Caillon, E Batard.   

Abstract

Ciprofloxacin and cotrimoxazole are recommended to treat uncomplicated pyelonephritis and uncomplicated cystitis, respectively, provided that local resistance rates of uropathogens do not exceed specified thresholds (10 and 20 %, respectively). However, Escherichia coli resistance rates in Emergency Departments (ED) remain poorly described. Our objectives were to assess E. coli ciprofloxacin and cotrimoxazole resistance rates in EDs of a French administrative region, and to determine if resistance rates differ between EDs. This was a retrospective study of E. coli urine isolates sampled in ten EDs between 2007 and 2012. The following risk factors for resistance were tested using logistic regression: ED, sex, age, sampling year, sampling month. A total of 17,527 isolates were included. Ciprofloxacin local resistance rates (range, 5.3 % [95 % CI, 4.0-7.1 %] to 11.7 % [95 % CI, 5.2-23.2 %]) were ≤10 % in nine EDs in 2012. Five EDs were risk factors for ciprofloxacin resistance, as were male sex, age and sampling in April or October. Cotrimoxazole local resistance rates (range, 13.3 % [95 % CI, 6.3-25.1 %] to 20.4 % [95 % CI, 18.9-22.0 %]) were ≤20 % in seven EDs in 2012. Five EDs were risk factors for cotrimoxazole resistance, as were age, sampling between October and December, and sampling in 2011 and 2012. We found a significant variability of E. coli ciprofloxacin and cotrimoxazole resistance rates among EDs of a small region. These differences impact on the feasibility of empirical treatment of urinary tract infections with ciprofloxacin or cotrimoxazole in a given ED. Continuous local survey of antibacterial resistance in ED urinary isolates is warranted to guide antibacterial therapy of urinary tract infections.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25339200     DOI: 10.1007/s10096-014-2264-y

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  18 in total

1.  High rates of quinolone resistance among urinary tract infections in the ED.

Authors:  Thana Khawcharoenporn; Shawn Vasoo; Edward Ward; Kamaljit Singh
Journal:  Am J Emerg Med       Date:  2010-11-13       Impact factor: 2.469

2.  Influence of fluoroquinolone consumption in inpatients and outpatients on ciprofloxacin-resistant Escherichia coli in a university hospital.

Authors:  A Gallini; E Degris; M Desplas; R Bourrel; M Archambaud; J-L Montastruc; M Lapeyre-Mestre; A Sommet
Journal:  J Antimicrob Chemother       Date:  2010-09-27       Impact factor: 5.790

Review 3.  International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases.

Authors:  Kalpana Gupta; Thomas M Hooton; Kurt G Naber; Björn Wullt; Richard Colgan; Loren G Miller; Gregory J Moran; Lindsay E Nicolle; Raul Raz; Anthony J Schaeffer; David E Soper
Journal:  Clin Infect Dis       Date:  2011-03-01       Impact factor: 9.079

4.  Evolution of fluoroquinolone resistance among Escherichia coli urinary tract isolates from a French university hospital: application of the dynamic regression model.

Authors:  A Mahamat; J P Lavigne; P Fabbro-Peray; J M Kinowski; J P Daurès; A Sotto
Journal:  Clin Microbiol Infect       Date:  2005-04       Impact factor: 8.067

5.  Antimicrobial resistance in uncomplicated urinary tract infections in 3 California EDs.

Authors:  Shannon E Moffett; Bradley W Frazee; John C Stein; Bahar Navab; Judy Maselli; Sukhjit S Takhar; Ralph Gonzales
Journal:  Am J Emerg Med       Date:  2011-07-29       Impact factor: 2.469

6.  The impact of antibiotic use on the incidence and resistance pattern of extended-spectrum beta-lactamase-producing bacteria in primary and secondary healthcare settings.

Authors:  Mamoon A Aldeyab; Stephan Harbarth; Nathalie Vernaz; Mary P Kearney; Michael G Scott; Feras W Darwish Elhajji; Motasem A Aldiab; James C McElnay
Journal:  Br J Clin Pharmacol       Date:  2012-07       Impact factor: 4.335

7.  Seasonality and temporal correlation between community antibiotic use and resistance in the United States.

Authors:  Lova Sun; Eili Y Klein; Ramanan Laxminarayan
Journal:  Clin Infect Dis       Date:  2012-07-01       Impact factor: 9.079

8.  Age, nursing home residence, and presentation of urinary tract infection in U.S. emergency departments, 2001-2008.

Authors:  Jeffrey M Caterino; Sarah A Ting; Sarah G Sisbarro; Janice A Espinola; Carlos A Camargo
Journal:  Acad Emerg Med       Date:  2012-10       Impact factor: 3.451

9.  Susceptibility to the main antibiotics of Escherichia coli and Staphylococcus aureus strains identified in community acquired infections in France (MedQual, 2004-2007).

Authors:  S Thibaut; J Caillon; C Huart; G Grandjean; P Lombrail; G Potel; F Ballereau
Journal:  Med Mal Infect       Date:  2009-10-17       Impact factor: 2.152

10.  Relationship between hospital antibiotic use and quinolone resistance in Escherichia coli.

Authors:  Eric Batard; Florence Ollivier; David Boutoille; Jean-Benoît Hardouin; Emmanuel Montassier; Jocelyne Caillon; Françoise Ballereau
Journal:  Int J Infect Dis       Date:  2012-11-22       Impact factor: 3.623

View more
  2 in total

1.  Antibiotic resistance patterns of Escherichia coli urinary isolates and comparison with antibiotic consumption data over 10 years, 2005-2014.

Authors:  P J Stapleton; D J Lundon; R McWade; N Scanlon; M M Hannan; F O'Kelly; M Lynch
Journal:  Ir J Med Sci       Date:  2017-01-04       Impact factor: 1.568

2.  Temporal trends and risks factors for antimicrobial resistant Enterobacteriaceae urinary isolates from outpatients in Guadeloupe.

Authors:  Stéphanie Guyomard-Rabenirina; Joyce Malespine; Célia Ducat; Syndia Sadikalay; Mélanie Falord; Dorothée Harrois; Vincent Richard; Charles Dozois; Sébastien Breurec; Antoine Talarmin
Journal:  BMC Microbiol       Date:  2016-06-24       Impact factor: 3.605

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.